跳至主要内容
临床试验/NCT00131924
NCT00131924终止2 期

Phase II Study of High-Dose Estrogen in Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapies

Northwestern University2 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2004年3月最近更新:
适应症

试验速览

阶段
2 期
状态
终止
入组人数
1
试验地点
2
主要终点
Clinical response rate

研究概览

简要总结

RATIONALE: High doses of esterified estrogens may stop the growth of breast cancer cells that no longer respond to hormone therapy.

PURPOSE: This phase II trial is studying how well high-dose esterified estrogens work in treating postmenopausal women with metastatic breast cancer that has failed previous hormone therapy.

详细描述

OBJECTIVES:

Primary

  • Determine the clinical response rate in postmenopausal women with estrogen and/or progesterone receptor-positive metastatic breast cancer that has failed prior sequential endocrine therapy treated with high-dose esterified estrogens (Menest^®).

Secondary

  • Determine time to disease progression in patients treated with this drug.
  • Determine the toxic effects of this drug in these patients.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Clinical response rate

次要结局

  • Time to disease progression
  • Toxicity

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验